MCL-1依赖性作为侵袭性B细胞淋巴瘤的一种新的脆弱性。 - Suppr

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.

作者信息

Wang Michelle Y, Li Tao, Ren Yuan, Shah Bijal D, Lwin Tint, Gao Jing, Shain Kenneth H, Zhang Wei, Zhao Xiaohong, Tao Jianguo

机构信息

Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.

出版信息

Blood Cancer J. 2021 Jan 14;11(1):14. doi: 10.1038/s41408-020-00402-2.

DOI:10.1038/s41408-020-00402-2

PMID:33446629

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7809345/

Abstract

摘要

相似文献

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.

Blood Cancer J. 2021 Jan 14;11(1):14. doi: 10.1038/s41408-020-00402-2.

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.

Int J Mol Sci. 2019 Nov 30;20(23):6036. doi: 10.3390/ijms20236036.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal in Relapsed Mantle Cell Lymphoma.

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.

BMC Cancer. 2018 Nov 16;18(1):1129. doi: 10.1186/s12885-018-5018-x.

Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.

Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3739-3753. doi: 10.1016/j.bbadis.2018.09.010. Epub 2018 Sep 11.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Oncotarget. 2015 Apr 20;6(11):8750-9. doi: 10.18632/oncotarget.3275.

Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.

Sci Rep. 2017 Dec 21;7(1):18007. doi: 10.1038/s41598-017-18368-w.

Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model.

Exp Biol Med (Maywood). 2019 Aug;244(11):865-872. doi: 10.1177/1535370219857594. Epub 2019 Jun 17.

Humanized mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.

Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405. Epub 2018 Aug 23.

引用本文的文献

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.

Cell Death Dis. 2023 Nov 2;14(11):714. doi: 10.1038/s41419-023-06233-w.

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.

Commun Med (Lond). 2023 Oct 25;3(1):154. doi: 10.1038/s43856-023-00380-z.

Targeting MCL-1 protein to treat cancer: opportunities and challenges.

Front Oncol. 2023 Jul 31;13:1226289. doi: 10.3389/fonc.2023.1226289. eCollection 2023.

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.

Cell Death Differ. 2023 Apr;30(4):1005-1017. doi: 10.1038/s41418-023-01117-0. Epub 2023 Feb 8.

本文引用的文献

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.

Cancers (Basel). 2020 Apr 10;12(4):938. doi: 10.3390/cancers12040938.

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.

Int J Mol Sci. 2019 Nov 30;20(23):6036. doi: 10.3390/ijms20236036.

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.

Oncogene. 2020 Feb;39(9):2009-2023. doi: 10.1038/s41388-019-1122-x. Epub 2019 Nov 26.

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Sci Transl Med. 2019 Oct 30;11(516). doi: 10.1126/scitranslmed.aax2863.

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005.

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004.

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.

J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5.

Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

Br J Haematol. 2019 Jan;184(2):298-302. doi: 10.1111/bjh.15079. Epub 2018 Jan 30.

Pathology and classification of aggressive mature B-cell lymphomas.

Hematol Oncol. 2017 Jun;35 Suppl 1:80-83. doi: 10.1002/hon.2406.

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Nat Commun. 2017 Apr 18;8:14920. doi: 10.1038/ncomms14920.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献